Posts by vagnum

PLX

low 4.85$ High 5.95$

FDA Extends Taliglucerase Alfa PDUFA Date to May 1, 2012

http://prn.to/rWCBmN

Hot Pharma Stocks / Ideen / Blockbuster

b00n wrote:

Quote

was geht da?

Peregrine Pharmaceuticals(NASDAQ:PPHM)

P2 Daten

Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial

http://bit.ly/syPrqM

200dma @ 1.70$ aktuell

gap offen bei 0.99$

AMWI 0.495$

hab viel auf dem tisch liegen lassen... ooch

gewinn ist gewinn.

Nano- and Microcap Stocks

out ZOOm 1.64$

out 2/3 AMWI 0.31

later...

PLX

Protalix Announces Successful European GMP Audit

Quote:

Quote

CARMIEL, Israel, Dec. 1, 2011 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE:PLX), announced today that the Irish Medicines Board (IMB) has completed a successful GMP (Good Manufacturing Practice) audit of the Company's manufacturing facility in Carmiel, Israel, and has issued a Certificate of GMP Compliance of a Manufacturer for the facility. The IMB Certificate is accepted by all health authorities in the European Union (EU) under the EU's centralized marketing authorization procedure, and by authorities of several other countries that recognize EU Certification. The audit was performed as part of the European Medicines Agency's (EMA) evaluation of the Marketing Authorization Application for taliglucerase alfa for the treatment of Gaucher disease.

In addition to the EMA, the U.S. Food and Drug Administration (FDA), Israeli Ministry of Health and Brazilian National Health Surveillance Agency have completed audits of the Company's manufacturing facility and deemed the facility acceptable.

"We are pleased to accomplish this major regulatory milestone," said Dr. Michal Kahana, Protalix's Vice President of Quality Affairs. "This important achievement helps demonstrate the viability of our proprietary plant-cell based technology platform, which is the engine behind all our pipeline candidates."

To date, marketing applications for taliglucerase alfa have been submitted in the United States, European Union, Brazil, Israel and Australia. The Prescription Drug User Fee Act (PDUFA) target date for taliglucerase alfa in the United States is February 1, 2012.

[Blocked Image: http://img685.imageshack.us/img685/5592/plx.th.png]

http://prn.to/thn6VG

RIGH - TOFS

RIGH @ 8 !!!

+ 400%

TOFS dürfte im Dezember auch wieder auf 5-6 zulegen. swing time, mmn.

heute ist erster handelstag im dezember.

gruess

INHX 16.15$

rocket science!

Quote:

Quote

Bio-pharmaceutical company Inhibitex, Inc.'s (NASDAQ: INHX ) shares advanced 20.18% to close at $13.70 after the company announced it plans to expand studies of its experimental hepatitis C treatment

Read more: http://community.nasdaq.com/Ne…ryid=105851#ixzz1fJ9smOrJ

http://bit.ly/uWaP3y

ZOOM 1.20$

erstes gap bei 1.23 geschlossen. weiteres gap bei 1.50$!

hab gestern schon über diese Aktie geschrieben, das posting aber wieder gelöscht da ich die aktie noch nicht so gut kenne. so wies aussieht covern hier die shorts erstmal. Volumen ist gut heute.

weitere interessante titel TSON, REEI, BIOF, RAYS, PEIX, EEE und CARV...

AMWI on track 0.195$ hält soweit.

Alle hier gennanten Titel sind risikohaft und nicht zum investieren geeignet.

gruss

AMWI 0.22$

endlich tut sich sich was und die Aktie ist über 0.20$ geklettert. Jetzt sollte 0.195$ als Unterstützung dienen und darf per Tagesschlusskurs nicht nach unten durchbrochen werden. 0.30$ als Ziel?

gruss

DEAR 0.30$

Dearborn Bancorp to Delist From Nasdaq and Commence Quotation on OTC Markets

Quote:

Quote

DEARBORN, Mich., Nov 23, 2011 (GlobeNewswire via COMTEX) -- Dearborn Bancorp, Inc. DEAR -37.50% , the Holding Company for Fidelity Bank, today announced that it received a letter from The Nasdaq Stock Market stating that the staff has rejected the Company's compliance plan to cure a reporting deficiency under Listing Rule 5250(c)(1) for the reasons detailed below. The letter provides that, absent an appeal of the staff's determination by the Company, trading in the Company's common stock will be suspended at the opening of business on November 29, 2011, and Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission to remove the Company's securities from listing and registration on Nasdaq.

As previously reported on August 19, 2011, the Company received a letter from Nasdaq on August 18, 2011 stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company did not timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2011 with the SEC. The Company submitted a compliance plan to Nasdaq in a timely fashion, however, due to the timing of the annual examination of its wholly owned subsidiary Fidelity Bank, and management's inability to certify the Company's financial statements until resolution of its disagreement with the FDIC on certain accounting and regulatory issues, the Company could not assure Nasdaq that it would be in compliance with Listing Rule 5250(c)(1) by the required deadline. As such, the Company's compliance plan was not accepted.

The Company has the right to appeal the Nasdaq staff's determination to suspend trading in the Company's securities and its delisting and deregistration from Nasdaq, but does not expect to do so, due, in part, to the Company's belief that the interests of the Company and its shareholders will be better served at the present time through cost savings afforded by delisting from Nasdaq.

Effective Monday, November 28, 2011, the Company anticipates that transactions in the Company's stock will be reported on the OTC Pink, Limited Information, under the symbol DEAR. The Company's common stock will cease trading on Nasdaq at the opening of the market on Tuesday, November 29, 2011 and will be quoted through the facilities of the OTC Markets Group, Inc. Investors will be able to view Level II real time stock quotes for DEAR at http://www.otcmarkets.com .

Dearborn Bancorp, Inc. is a registered bank holding company. Its sole banking subsidiary is Fidelity Bank. The Bank operates 15 offices in Wayne, Oakland, Macomb and Washtenaw counties in the State of Michigan.

Display More

http://bit.ly/uUVhi5

Nano- and Microcap Stocks

@ MMoser guter call NVIV lief von 2.50$ auf 2.95$

_______________________________________________________

Rays wieder bei 2.00$. hab hier keine posi seit meiner kapitulation. wir stehen etwa da, wo wir kurz vor dem crash gestanden sind der weg zu 3.50$ ist wieder offen aber ich traue dem daily MACD nicht, sieht nach kommender konso aus und ansonsten heissts dann wohl buy the crash or the breakout. aktuelle marketcap 93Millionen.

______________________________________________________

AMWI 0.18$ bin fast eingeschlafen beim zuschauen.

Hot Pharma Stocks / Ideen / Blockbuster

b00n wrote:

Quote

ja unsere ersten INHX einträge hier waren ziemlich genau vor einem jahr, also unter 2 bucks..

[Blocked Image: http://bernetblog.ch/wp-conten…ir-knopf-von-facebook.jpg]

dessweiteren INHX

http://www.inhibitex.com/Pipeline/Default.htm

der 2te anstieg ist ja wegen VRUS...

INHX 11.70$

Inhibitex läuft wie das Energizer Bunny :idea:

http://www.google.com/finance?q=inhx

TSPT 6.70$

Transcept Intermezzo Approved by FDA

Quote:

Quote

November 23, 2011 1:05 PM EST

The U.S. Food and Drug Administration today approved Transcept's (Nasdaq: TSPT) Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.

This is the first time the FDA has approved a drug for this condition. Intermezzo should only be used when a person has at least four hours of bedtime remaining. It should not be taken if alcohol has been consumed or with any other sleep aid.

Insomnia is a common condition in which a person has trouble falling or staying asleep. It can range from mild to severe, depending on how often it occurs and for how long. Insomnia can cause excessive daytime sleepiness and lack of energy. It also can make a person feel anxious, depressed, or irritable. People with insomnia may have trouble focusing on tasks, paying attention, learning, and remembering.

Zolpidem tartrate was first approved in the United States in 1992 as the drug Ambien. Intermezzo is a lower dose formulation of zolpidem. The recommended and maximum dose of Intermezzo is 1.75 milligrams for women and 3.5 mg for men, taken once per night. The recommended dose for women is lower because women clear zolpidem from the body at a lower rate than men.

“For people whose insomnia causes them to wake in middle of the night with difficulty returning to sleep, this new medication offers a safer choice than taking a higher dose of zolpidem upon waking,” said Robert Temple, M.D., deputy center director for clinical science in the FDA’s Center for Drug Evaluation and Research. “With this lower dose there is less risk of a person having too much drug in the body upon waking, which can cause dangerous drowsiness and impair driving.”

Intermezzo was studied in two clinical trials involving more than 370 patients. In the studies, patients taking the drug had a shorter time to fall back asleep after waking compared to people taking an inactive pill (placebo). The most commonly reported adverse reactions in the clinical trials were headache, nausea and fatigue.

Like other sleep medicines, Intermezzo may cause serious side effects, including getting out of bed while not fully awake and doing an activity that you do not know you are doing or do not remember having done. Reported activities while under the influence of sleep medicines include driving a car, making and eating food, having sex, talking on the phone, and sleep walking—without knowing at the time or remembering later. Chances of such activity increase if a person has consumed alcohol or taken other medicines that make them sleepy.

Intermezzo is a federally controlled substance because it can be abused or lead to dependence.

Intermezzo is made by Transcept Pharmaceuticals Inc. of Port Richmond, Calif.

Display More

http://bit.ly/ujQTN3

AVNR 2.13$

@ blabla

vielen dank für deine recherchen. das bringts!

tut mir leid, dass dich AVNR ufregt aber allgemein im markt ist die stimmung wohl schlecht kann man sagen. ist sicher nicht einfach ein produkt wie nuedexta an den/die Mann/Frau zu bringen bei dieser marktlage. die analysten haben die ziele für avanir hoch gesteckt jedoch gelten diese wohl nur für einen positiven markt würd ich mal behaupten. Per's 2.00$ level ist schon fast erreicht. ich glaube nicht, dass es viel weiter runter geht bis ende jahr da auch das volumen sehr klein ist, mit dem sie den Preis runterbringen.

jetzt gehts darum bottom fishing zu betreiben und möglichsts nahe dem tief einsteigen zu können für einen profitablen handel. AVNR hat unter anderem den nächsten earnings release am 30.11.2011.

gruess

Avanir Pharmaceuticals [AVNR]

----double post----

Re: AMWI 0.19$

vagnum wrote:

Quote

Hab AMWI auf close watch. das könnte wieder einen 30-100% runner geben. ist risky aber mal sehn...

Die Aktie hat sich von 0.03$ auf 0.21$ verteuert in einem tag. der tageschart ist im moment noch in der seitwärtsphase aber schon nächste Woche werden wir wissen wie viel da noch geht.

marktcap bei 0.186$ ist 87Mil.

have a nice weekend.

http://finance.yahoo.com/q?s=AMWI.OB

Display More

AMWI immernoch bei 0.19$.

Nano- and Microcap Stocks

todays scan:

[Blocked Image: http://img855.imageshack.us/img855/292/unbenanntvp.png]

Nano- and Microcap Stocks

@b00n haltest du 1er bei APCX?

EEGC sehe ich 0.03 möglich, denke sie gehen dorthin wo die kerze vom 9.11 ihr high hat, vlt ein bisschen drüber. geht aber nur sehr langsam voran.

TOFS und RIGH weiterhin sehr gedige zum verfolgen. Tandem play würde ich sagen.

Avanir Pharmaceuticals [AVNR]

Per wrote:

Quote

übel, übel !

da hats wohl einige erwischt. hoffe es ist niemand von euch drinnen geblieben. die haben einen riesigen sales staff und können N nicht wirklich gut vermarkten. wo führt das noch hin ??

uhmm danke für den alert? :roll:

glaub nicht, dass es jemanden erwischt hat. konnten doch alle mit gewinn verkaufen....

was denkst du, wo würdest du bei AVNR wieder einsteigen?

gruess